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Introduction
Systemic Lupus Erythematosus (SLE) is 
a systemic autoimmune disease that targeted 
to multi organs with various manifestations. 
This disease affected mostly young women. 
The most cause of mortality in SLE patients is 
infection.1 Aspergillus infection is commonly 
found in the SLE population. Primary 
immunity dysfunction in SLE and regimen 
therapy, such as pulse dose corticosteroids, long 
term corticosteroids, immunosuppressant, and 
biological agents increase the risk of infection in 
SLE. Based on a study in New York, among 233 
SLE patients, there were 150 cases of infection, 
of which 23 were opportunistic infection: 12 
were candidiasis while 11 others were deep 
fungal infection.2 In a retrospective study from 
Taipei with a total of 6714 subjects, 393 cases 
met the criteria for inclusion. Cryptococcus 
spp., Aspergillus spp., and Candida spp. were 
the most common fungal pathogens. Cohorts 
described Invasive Fungal Disease (IFD) in 
0.6-3.2% of SLE inpatients and 0.28% of SLE 
outpatients. IFD occurred at a median of 2 
years of disease duration (IQR: 0.5-7.1), and 
39% of cases occurred within the first year of 
SLE. Disease activity and corticosteroid dose 
>60mg/day emerged as risk factors for IFD. 
IFD was associated with a mortality rate of 
53% (161/316 cases), and worse in the absence 
of antifungal therapy (n = 43).3 
The  recommendat ion of  Severe 
SLE management by American College 
Rheumatology (ACR), European League 
Against  Rheumat i sm (EULAR),  and 
Indonesian Rheumatology Association (IRA) 
suggest to give pulse dose steroid 500 mg - 1 gr 
for 3 days, and if it does not give an adequate 
response, continued with cyclophosphamide 
(CYC) injection 500-750 mg/m2 per month 
then every 3 months thereafter depending on 
clinical response. The usual duration therapy 
is 2-2.5 years.1,4,5 Therapy of pulse dose 
corticosteroids, long-term corticosteroids, 
and immunosuppressants can significantly 
increase the risk of aspergillus infection. A 
study by Hung et.al, reported that high daily 
steroid dosing, recent pulse steroid therapy, 
azathioprine, rituximab, concurrent infections, 
and CMV viremia were mortality risk factors 
for invasive Aspergillosis (IA) in SLE.3
In this case, a Severe SLE patient was in 
the third of 28-days-cycle cyclophosphamide 
chemotherapy when the early symptoms 
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of aspergillus infection occurred. This then 
developed into extensive cranial bone damage. 
Later it was planned to get a biopsy and 
debridement for bone and soft tissue to diagnose 
and therapy palate osteonecrosis, followed by 
reconstruction surgery. This case report aimed 
to report the successful management of a severe 
patient on chemotherapy undergoing several 
operations so that the SLE aspergillosis is 
optimally managed.
Case
A 21 years old single woman who has been 
diagnosed with SLE since 2009 had arthritis, 
mucocutan, serositis, vasculitis, nephritis, Anti-
Nuclear Antibody (ANA) positive, and dsDNA 
positive as the early manifestations. From 2009 
until 2018, the SLE activity fluctuated but still 
could be controlled with oral medications. 
Since September 2018, she has been receiving 
28-days-cycle CYC chemotherapy to treat 
the nephritis manifestation. In the third 
chemotherapy on December 21st, 2018, she felt 
a lesion on her hard palate, then followed with 
swelling gums with red edges, and unsteady 
teeth. Some weeks later, her teeth started 
falling out without any pain. The lession on her 
palate widened until torn her palatal mucosa. 
She sometimes felt mild fever, congested nose, 
rhinorrhea with a serous secret and unpleasant 
smell. However, she did not feel any arthritis, 
mouth ulcer, hair loss, photosensitivity, fever, 
cough, breathlessness, vomit, difficulty in 
defecation, and urination. The routine therapy 
at that time was Mycofenolat Acid (MPA) 2 
x 360 mg, Methylprednisolone 4 mg 1-1-0, 
Cetirizine 1 x 10 mg, Irbesartan 1 x 300 mg 
other than CYC chemotherapy every 28 days. 
The physical examination, obtained 
moderate pain, fully alert, underweight with 
BMI 14.2 kg/m2 and BSA 1.2 m2. The blood 
pressure was 112/75 mmHg, the pulse rate was 
78x/min, the respiratory rate was 20x/min, 
and the temperature was 36.7o Celsius. There 
was diffuse alopecia, hyper pigmented malar 
rash on her face, and unpainful red swelling 
under her right eye. Dry and cracked lips were 
found. In the mouth cavity, her hard palate 
tore until half of the surface demonstrating a 
yellowish-white tissue was visualized, mouth 
mucosal tissue was pale with red edges and 
irregular but it was not soft and fragile, with 
no bleeding or pus. Some of the superior molar 
teeth had fallen. Her thorax, heart, lung, and 
abdomen were normal. There was minimal 
Figure 1. Patient’s condition before and after suffered Invasive Aspergillosis.
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pitting edema on her feet. The patient’s MEX 
SLEDAI score was moderate activity (renal 
dysfunction, mucocutan, and mucosal ulcer). 
Complete blood examination oin 
December 19th, 2018 showed Hb 10.6 d/dl, 
Leucocyte 11.92.103 /mm3, Platelet 417.103 
/mm3, Segment 82, Lim 14.3, Mon 3.6, 
Eos 0, Bas 0.1, Neutrophil Count 9780/
mm3, Lymphocyte Count 1700/mm3, IGRA 
negative, BUN 8mg/dl, Creatinin 0.54 mg/dl, 
Blood glucose 120 mg/dl, SGOT 18 md/dl, 
SGPT 5mg/dl ,Albumin 2.75 mg/dl, Sodium 
134 meq/l, Potassium 3.81 meq/l, Chloride 
99 meq/l.
Routine urine examination revealed clear 
yellow, normal smell, pH 7, density 1.015, Bil.-
, Uro. Normal, Ket.-, Nit.-, Leukocyte Esterase 
-, RBC 22, Blood neg, Leu 14, Glucose neg, 
Prot +2, Bacteria 18.4, Yeast 0, Small round 
cell 25.3, Sil pathologist (-). Chest Radiology 
and Electrocardiography result were normal.  
The patient was consulted to Mouth 
Surgery Outpatient Clinic, then plain and 
non-contrast Head MSCT was performed, 
and showing Bilateral frontotemporal 
Lobe Atrophy, Cavum Vergae Dilatation, 
Pansinusitis, Osteodistruction of Bilateral 
maxillary Bones, Bilateral Zygomatic Bones, 
Right Frontal Bone, Bilateral Temporal Bones, 
Sphenoidal Bone, and Right Mastoiditis. 
Nasoendoscpy was performed by 
otorhinolaryngology showing Atrophic 
turbinate, Oronasal fistula, and discharge 
from medial meatal. The differential diagnoses 
after discussing with mouth surgery and ENT 
department were: Chronic RhinoSinusitis, 
Soft palate ulcer, maxillary/zygomatic/
frontal/ethmoid osteonecrosis due to SLE 
DD osteonecrosis induced corticosteroids 
DD le tha l  mid l ine  g ranuloma.  The 
therapy was Nasogastric Tube for feeding, 
Amoxicillin-clavulanate 3x625mg, NAC 3x1, 
continuing CYC  chemotherapy, stopped 
methylprednisolone, planned for bone and soft 
palate biopsy if it was possible.
At that time, a biopsy could not be 
performed due to unstable SLE activity and 
she was still in CYC chemotherapy every 28 
days. If she underwent surgery at that time, the 
risk of bleeding and prolonged wound healing 
would increase. Thus, the biopsy was planned 
in the 3 months cycle of chemotherapy. While 
waiting for the 3-months-cycle chemotherapy, 
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On May 7th, 2019, or about 4 weeks 
after the first chemotherapy of the 3-months-
cycle chemotherapy, a biopsy of bone and soft 
tissue was performed in the hard palate and 
nasal area. During surgery, the bleeding was 
minimal and the wound healing was quick, 
so that 5 days after her surgery, she could go 
home. The histopathology results from the soft 
tissue biopsy were Maxillary tissues: Invasive 
Aspergillosis, Soft tissue between Maxilla and 
nasal cavity: The tissues covered by ciliated 
pseudostratified epithelia, it is likely from the 
aspergillosis infection. Bone biopsy: Alveolar 
biopsy: necrotic bone, Biopsy from the mucosal 
border: chronic inflammation of connective 
tissues, likely due to aspergillosis. At the time 
we did, the secret culture was not performed. 
The  therapy  a f te r  knowing  the 
histopathology result was continuing CYC 
chemotherapy 3 months cycle, Fluconazole 
50 mg per day, Irbesartan 1x300mg, and 
if there was no longer infection, the palate 
reconstructive surgery could be performed. 
After antifungal therapy for 6 months, the 
Figure 3. Head MSCT non-contrast (A) and contrast (B) Finding. 
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lesion improved, there were no new lession 
and granulation tissue began to grow. Repeated 
biopsy showed Aspergillus infection was 
overcome. However, she still had a mouth 
cavity and nasal deformities, causing her 
difficulty to speak and swallow. 
From October to December 2019, a 
reconstructive surgery by mouth surgeon, 
ENT, plastic surgeon, and the periodontal 
specialist was performed. The outcome of that 
surgery was satisfying. She got an obturator 
after removal of her damaged hard palate, and 
then placed the dentures. Finally, she could 
speak and eat well. 
Discussion
As it is recommended in SLE management, 
CYC is the therapy for severe SLE cases, such 
as nephritis, a neuropsychiatric disorder, 
severe thrombocytopenia autoimmune 
hemolytic anemia, severe pneumonitis, 
alveolar hemorrhage, abdominal vasculitis, 
and extensive skin disorder. This therapy is 
administered together with high or pulse-dose 
glucocorticoid which is continued with long-
term oral dose glucocorticoid.
Cyclophosphamide is one of the alkylating 
agents used for cancer and immunosuppression 
therapies. Cyclophosphamide is a prodrug 
changed in the liver into an active metabolite 
in the form of phosphoramide mustard, which 
then binds with DNA and RNA crosslinks 
and later inhibits the replication of DNA 
and protein synthesis. In low dose CYC 
function as immunosuppression through 
several mechanisms,  selectively depleting 
of Tregs and inhibition of their suppressive 
function; switching the secretion of cytokines 
from Th2 to Th1; and enhancement of Th17, 
memory, and effector CD8 T-cell phenotypes.7
The side effects of CYC may include nausea, 
vomiting, leukopenia, thrombocytopenia, 
alopecia, and anorexia. Other symptoms 
may include skin pigmentation, oral mucosal 
ulceration, and sterile hemorrhagic cystitis. 
It can also cause non-specific dermatitis, 
pigmentation of the nails, regrowth of hair, 
anemia, hematuria, fibrosis of the ovaries, 
gonadal suppression resulting in amenorrhea or 
Figure 4. Patient after therapy and reconstructive surgery.
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azoospermia, hemorrhagic colitis, and jaundice. 
It may result in damage to the hair follicles, 
short-term dizziness, transverse ridging of the 
nails, and hepatic toxicity. Secondary neoplasia 
and nephrotoxicity have also been reported. 
Other symptoms may involve skin irritation, 
gastrointestinal disturbances, and hepatic 
dysfunction. High doses over a prolonged 
period can cause interstitial pulmonary fibrosis. 
Other symptoms of exposure may comprise 
granulocytopenia (causing susceptibility 
to infection and opportunistic infection), 
myocardial damage, interstitial pneumonia, 
and hypoplasia of all elements of bone marrow. 
It has been known to cause blurred vision, 
pulmonary fibrosis, cardiomyopathy, and 
sterility. Fetal abnormalities can occur if it 
is ingested during pregnancy. Eye contact 
can cause transient blurring of vision, dry 
eye syndrome, viral and another keratitis, 
and severe keratoconjunctivitis associated 
with graft-versus-host disease leading to 
scarring of the corneas. It may also result in 
lymphocytopenia.8
This patient is an SLE patient who was 
diagnosed 9 years ago. She had an unstable 
SLE activity. Long-term corticosteroids 
consumption and immune-suppressants led 
her to an immune-compromised condition. 
In the late 3 months before infection, she got 
pulse dose steroid as lupus nephritis indication, 
then followed with CYC chemotherapy. These 
conditions depressed her immunity more. This 
immune-compromised condition caused her to 
suffer from severe aspergillus infection formed 
as sinus invasive aspergillosis of extrapulmonary 
aspergillosis. There was a relationship between a 
low level of neutrophil and Invasive Aspergillus 
Infection. A neutrophil is innate immune 
protection and the first line against infections 
such as aspergillus and candida. In neutropenic 
patients, the lack of host response is associated 
with rapid growth, which induces necrosis of 
host tissues and facilitates fungal nutrition.
Our patient’s complaints were matched 
with sinusitis aspergillosis manifestations such 
as fluctuating fever, headache, nasal congestion, 
and rhinorrhea, widened lesion in palate until 
some teeth fell out without any pain. Invasions 
to the brain, eyes, and skin were not found. 
Lung, heart and abdominal examination were 
normal. From Head MSCT both plain and 
contrasted imaging, there was thickening of 
mucosal walls in the bilateral maxillary, bilateral 
ethmoid, sphenoidal, and frontal sinuses. Air 
cellular mastoid was decreased, destructions 
in right maxillary bone, right zygomatic bone, 
right frontal bone, bilateral temporal bones, 
and sphenoid bone. The findings of the Head 
MSCT supported bilateral frontotemporal 
Lobe Atrophy, Cavum Vergae Dilatation, 
Pansinusitis, Osteodistruction of Bilateral 
maxillary Bones, Bilateral Zygomatic Bones, 
Right Frontal Bone, Bilateral Temporal Bones, 
Sphenoidal Bone, and Right Mastoiditis. 
However, this result could not show specifically 
of any invasive aspergillosis. The non-specific 
CT imaging did not show mass, bony 
dehiscence, thickening of extraocular muscles, 
inflammatory changes of the orbital and orbital 
apex, or mucus secretions. We used MRI is 
used to evaluate soft tissue widening from sinus 
to pericentral fat, sinus cavernosus, and brain. 
Her palate bone and soft tissue histopathology 
result showed invasive aspergillosis with bone 
and soft tissue destruction. As in the EORTC/
MSG Consensus, the patient was diagnosed 
with Proven Invasive Fungal Disease.
Several therapeutic strategies have been 
applied in an attempt to improve the outcome 
of IA. These include the introduction of 
potent antifungal agents, surgical excision of 
sequestered necrotic lesions; and, in selected 
patients, and the use of immune-modulating 
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agents such as in neutropenic patients. In our 
case, a set of operations were done, starting 
from biopsy until a few maxillary bone 
reconstructive surgeries due to severe damage.
The problem is out the case was the right 
timing for performing surgery, our patient was 
still in unstable SLE condition and on CYC 
therapy. To date, there has been no guideline 
or recommendation regarding perioperative 
management of severe SLE patients undergoing 
CYC therapy. Several considerations in 
conducting surgical procedure are:
1.  SLE patients suffer from a higher rate 
of infections, which appears it is related 
to both an intrinsic susceptibility and 
treatment-related immunosuppression. 
Immunological dysfunction may be due to 
functional asplenia, impaired complement 
system, and mannose-binding lectin 
deficiency, a serum protein that binds 
mannose in the bacterial wall and activates 
the complement system.9
2.  Prolonged postoperative wound healing in 
patients with immunosuppression.10
3.  The side effect of CYC therapy in the form of 
cardio-toxicity is a recognized complication 
of high-dose cyclophosphamide therapy, 
with acute decompensation. 9
4.  Medullar  suppress ion is  the most 
important toxic effect caused by almost all 
chemotherapeutic drugs, except bleomycin 
and vincristine. There are lymphocytopenia, 
variable thrombocytopenia degrees, 
erythropenia and hemophilic, anemia. 
Neutropenia or  lymphopenia  arising 
secondary to CYC usage can predispose 
people to a variety of bacterial,  fungal, 
and opportunistic infections. 10 
5. Cyclophosphamide reduces plasma 
pseudocholinesterase concentrations 
which may las t  for  severa l  weeks 
after infusion, leading to prolonging 
the effect of succinylcholine, and may 
result in prolonged  neuromuscular 
blockade when administered concurrently 
with succinylcholine.10
Some studies suggested surgery between 
2 and 5 weeks after the last chemotherapy cycle. 
In practice, surgery is usually performed when 
the neutropenic window is overcome, normally 
resulting in a 3- to 4-week interval.11
In the Brazilian Technical Bases Manual, 
it is specified that adjuvant chemotherapy 
should be initiated, at the most, between 
30 and 60 days post-surgery. However, the 
time to be waited for undertaking the other 
chemotherapy cycles is not specified. 12
In our case, the first surgery was performed 
4 weeks after the first 3-month cycle of 
chemotherapy. The SLE activity was stable and 
the neutrophil count was within the normal 
limit. The surgery went well despite minimal 
bleeding which was manageable. The surgical 
wound was healed quickly without secondary 
infection. Five days after the surgery, the 
patient was discharged. Based on histological 
examination, the patient received an antifungal 
drug. Significant clinical improvement was 
achieved after 6 months of antifungal therapy. 
The tissue damage was no longer extensive 
granulation tissue started growing in the gum 
and palate.
The next surgical procedure performed was 
serial reconstruction which was conducted after 
the third 3-month cycle of cyclophosphamide 
chemotherapy, which was 4 weeks after 
chemotherapy. After the third 3-month-cycle 
chemotherapy, the activity of SLE was mild and 
stable so that cyclophosphamide chemotherapy 
was stopped and continued with oral DMARD 
consisting of MPA and a low dose of Methyl 
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Prednisolone. The whole set of reconstruction 
surgery went well without postoperative 
complication as well as stable SLE with mild 
activity.
 Conclusion
Sys t emic  Lupus  Er y thematosus 
patients have a high risk to suffer from 
invasive aspergillosis due to immune-
compromised conditions caused by SLE 
immunity dysregulation, consumption of 
immunosuppressant agents, high dose and long 
term intake of corticosteroids. 
Invasive aspergillosis therapy inpatient 
undergoing chemotherapy comprises the 
combination of antifungal drugs, surgery, and 
chemotherapy dose reduction. In SLE patients 
receiving CYC, it is required to be cautious 
when choosing the right time for surgery 
between chemotherapies to obtain well-
controlled SLE with good surgical outcomes.
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